{"id":70759,"date":"2026-05-12T10:48:03","date_gmt":"2026-05-12T10:48:03","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=70759"},"modified":"2026-05-21T07:14:09","modified_gmt":"2026-05-21T07:14:09","slug":"survodutide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/survodutide\/","title":{"rendered":"Survodutide"},"content":{"rendered":"

<\/p>\n

\n

Rychl\u00e1 odpov\u011b\u010f \u2014 Co je Survodutide?<\/h3>\n

Survodutide<\/strong> (v\u00fdvojov\u00fd k\u00f3d BI 456906) je dlouhodob\u011b p\u016fsob\u00edc\u00ed dvojit\u00fd agonista receptor\u016f GLP-1 a glukagonu o d\u00e9lce 29 aminokyselin, kter\u00fd spole\u010dn\u011b vyvinuly spole\u010dnosti Boehringer Ingelheim a Zealand Pharma. Ve zve\u0159ejn\u011bn\u00e9 studii f\u00e1ze 2 vykazoval v\u00fdrazn\u00e9 \u00fa\u010dinky na MASH (metabolickou dysfunkc\u00ed spojenou se steatohepatitidou) a jatern\u00ed fibr\u00f3zu spolu s redukc\u00ed t\u011blesn\u00e9 hmotnosti u obezity o ~19 % za 46 t\u00fddn\u016f. Polo\u010das v plazm\u011b umo\u017e\u0148uje t\u00fddenn\u00ed d\u00e1vkov\u00e1n\u00ed. Dod\u00e1v\u00e1 se v lyofilizovan\u00fdch vial\u00e1ch o s\u00edle 5 mg a 10 mg pouze pro laboratorn\u00ed v\u00fdzkum.<\/p>\n<\/div>\n

Co z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdzkumn\u00e9 lyofilizovan\u00e9 peptidy \u00b7 HPLC \u010distota \u226599% (COA na vy\u017e\u00e1d\u00e1n\u00ed) \u00b7 Diskr\u00e9tn\u00ed teplotn\u011b stabiln\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 p\u0159eprava peptid\u016f \u00b7 1,400+ ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specifikace<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
CAS \u010d\u00edslo<\/strong><\/td>\n2230198-02-2 (survodutide; b\u011b\u017en\u011b uv\u00e1d\u011bno)<\/td>\n<\/tr>\n
Typ<\/strong><\/td>\nDlouhodob\u011b p\u016fsob\u00edc\u00ed dvojit\u00fd agonista receptor\u016f GLP-1 \/ glukagonu (acylovan\u00fd syntetick\u00fd peptid; Boehringer Ingelheim BI 456906; spole\u010dn\u00fd v\u00fdvoj se Zealand Pharma)<\/td>\n<\/tr>\n
item7<\/strong><\/td>\n~3 800 Da (s acylac\u00ed mastn\u00e9 kyseliny; zral\u00e1 peptidov\u00e1 forma)<\/td>\n<\/tr>\n
Struktura<\/strong><\/td>\n29-aminokyselinov\u00fd syntetick\u00fd peptidov\u00fd koagonista s upraven\u00fdmi substitucemi Aib pro odolnost v\u016f\u010di DPP-4 a mastnou diacylovou \u0159et\u011bzcovou skupinou p\u0159ipojenou na lysinov\u00fd zbytek prost\u0159ednictv\u00edm \u03b3-Glu spojky. V\u00fdrazn\u011b krat\u0161\u00ed ne\u017e dvojit\u00e9 agonisty odvozen\u00e9 od oxyntomodulinu (mazdutide ~39 aa), p\u0159i zachov\u00e1n\u00ed vyv\u00e1\u017een\u00e9 dvojit\u00e9 aktivity receptor\u016f GLP-1\/glukagonu.<\/td>\n<\/tr>\n
item11<\/strong><\/td>\nLyofilizovan\u00fd pr\u00e1\u0161ek (b\u00edl\u00fd a\u017e sv\u011btle \u017elut\u00fd)<\/td>\n<\/tr>\n
item13<\/strong><\/td>\n\u226599% (HPLC ov\u011b\u0159eno, COA na vy\u017e\u00e1d\u00e1n\u00ed)<\/td>\n<\/tr>\n
Skladov\u00e1n\u00ed<\/strong><\/td>\nLyofilizovan\u00e9: 2\u20138 \u00b0C (lednice) pro pracovn\u00ed z\u00e1sobu; \u221220 \u00b0C pro dlouhodob\u00e9 skladov\u00e1n\u00ed neotev\u0159en\u00fdch vialek. Rekonstituovan\u00e9: 2\u20138 \u00b0C, pou\u017eijte do ~30 dn\u016f. Chra\u0148te p\u0159ed sv\u011btlem. Nefreeze\u2013thaw rekonstituovan\u00fd roztok.<\/td>\n<\/tr>\n
Rozpustnost<\/strong><\/td>\nBakteriostatick\u00e1 voda (doporu\u010deno) nebo steriln\u00ed voda pro krat\u0161\u00ed dobu pou\u017eit\u00ed. Acylovan\u00e9 peptidy se mohou rozpou\u0161t\u011bt pomaleji \u2014 ponechte v\u00edce \u010dasu na vyrovn\u00e1n\u00ed.<\/td>\n<\/tr>\n
Pouze pro v\u00fdzkum<\/strong><\/td>\nPouze pro laboratorn\u00ed v\u00fdzkum. Nen\u00ed ur\u010deno pro diagnostick\u00e9 nebo terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed nebo zv\u00ed\u0159at.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

Co je Survodutide?<\/h2>\n

Survodutide<\/strong> (v\u00fdvojov\u00fd k\u00f3d BI 456906) je dlouhodob\u011b p\u016fsob\u00edc\u00ed dvojit\u00fd agonista receptor\u016f GLP-1 a glukagonu, kter\u00fd spole\u010dn\u011b vyvinuly spole\u010dnosti Boehringer Ingelheim a Zealand Pharma. P\u0159edstavuje z\u00e1padn\u00ed farmaceutickou v\u011btev v\u00fdzkumn\u00e9ho programu dvojit\u00fdch koagonist\u016f GLP-1\/glukagonu, vedle paraleln\u00edch program\u016f, kter\u00e9 vedly k v\u00fdvoji mazdutide<\/a> (Innovent Biologics, \u010c\u00edna) a star\u0161\u00ed slou\u010deniny Pegapamodutide \/ Cotadutide. Survodutide je strukturn\u011b kompaktn\u00ed \u2014 pouh\u00fdch 29 aminokyselin \u2014 v\u00fdrazn\u011b krat\u0161\u00ed ne\u017e dualistick\u00e9 agonisty odvozen\u00e9 od oxyntomodulinu, p\u0159i\u010dem\u017e zachov\u00e1v\u00e1 vyv\u00e1\u017eenou agonistickou aktivitu u obou c\u00edlov\u00fdch receptor\u016f d\u00edky in\u017een\u00fdrsk\u00fdm substituc\u00edm a acylaci mastnou kyselinou.<\/p>\n

Survodutide m\u00e1 zralou molekulovou hmotnost p\u0159ibli\u017en\u011b 3 800 Da v\u010detn\u011b acylov\u00e9 modifikace. D\u00e9lka 29 zbytk\u016f je jedn\u00edm ze struktur\u00e1ln\u00edch znak\u016f: krat\u0161\u00ed peptidy jsou obvykle levn\u011bj\u0161\u00ed na synt\u00e9zu na jednotku d\u00e1vky, ale maj\u00ed men\u0161\u00ed plochu pro jemn\u00e9 dolad\u011bn\u00ed farmakologie rovnov\u00e1hy receptor\u016f. Boehringer-Zealand dos\u00e1hl dualistick\u00e9 agonistick\u00e9 rovnov\u00e1hy kombinac\u00ed strategick\u00fdch substituc\u00ed Aib na m\u00edstech \u0161t\u011bpen\u00ed DPP-4 a pe\u010dliv\u00e9ho lad\u011bn\u00ed zbytk\u016f v\u00e1zaj\u00edc\u00edch se na receptory. Polo\u010das v plazm\u011b je p\u0159ibli\u017en\u011b 6 dn\u00ed, co\u017e umo\u017e\u0148uje t\u00fddenn\u00ed subkut\u00e1nn\u00ed d\u00e1vkov\u00e1n\u00ed.<\/p>\n

Aktu\u00e1ln\u00ed klinick\u00fd profil survodutidu je v\u00fdrazn\u00fd \u00fa\u010dinek na jatern\u00ed fibr\u00f3zu u MASH (metabolicky asociovan\u00e9 steatohepatitidy)<\/strong> hl\u00e1\u0161en\u00fd ve f\u00e1zi 2 klinick\u00e9ho hodnocen\u00ed \u2014 v\u00fdsledek, kter\u00fd jej odli\u0161uje od ostatn\u00edch dualistick\u00fdch a trojit\u00fdch agonist\u016f s podobn\u00fdmi \u00fa\u010dinky na t\u011blesnou hmotnost. Data z f\u00e1ze 2 u obezity uk\u00e1zala sn\u00ed\u017een\u00ed t\u011blesn\u00e9 hmotnosti p\u0159ibli\u017en\u011b o 19 % p\u0159i d\u00e1vce 4,8 mg t\u00fddn\u011b po dobu 46 t\u00fddn\u016f, co\u017e \u0159ad\u00ed survodutid do stejn\u00e9 \u00fa\u010dinnostn\u00ed kategorie jako tirzepatid a na hranici trojit\u00e9ho agonisty retatrutidu. Survodutid je aktu\u00e1ln\u011b ve f\u00e1zi 3 klinick\u00fdch hodnocen\u00ed pro obezitu (design studie ve stylu SURMOUNT) a MASH. Survodutid nen\u00ed FDA, EMA, MHRA ani \u017e\u00e1dn\u00fdm jin\u00fdm v\u00fdznamn\u00fdm regul\u00e1torem pro terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed. V\u00fdzkumn\u00fd DSIP prod\u00e1van\u00fd zde je dod\u00e1v\u00e1n<\/strong> schv\u00e1len FDA, EMA, MHRA ani \u017e\u00e1dn\u00fdm jin\u00fdm v\u00fdznamn\u00fdm regul\u00e1torem pro terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed. V\u00fdzkumn\u00fd survodutid prod\u00e1van\u00fd zde je dod\u00e1v\u00e1n ur\u010den pouze pro laboratorn\u00ed v\u00fdzkum<\/strong> a nen\u00ed ur\u010den pro pod\u00e1v\u00e1n\u00ed lidem nebo zv\u00ed\u0159at\u016fm. Pro sourozeneck\u00fd dualistick\u00fd agonista GLP-1\/glukagon viz na\u0161e Mazdutide<\/a> produktov\u00e1 str\u00e1nka; pro trojit\u00e9ho agonistu s p\u0159idan\u00fdm GIP viz Retatrutide<\/a>.<\/p>\n

Mechanismus \u00fa\u010dinku \u2014 Dualistick\u00fd agonismus receptor\u016f GLP-1 \/ glukagonu s d\u016frazem na j\u00e1tra<\/h2>\n

Co \u010din\u00ed survodutid mechanisticky v\u00fdjime\u010dn\u00fdm mezi dualistick\u00fdmi agonistick\u00fdmi metabolick\u00fdmi peptidy, je relativn\u011b vyv\u00e1\u017een\u00fd pom\u011br \u00fa\u010dinnosti GLP-1 k glukagonu<\/strong> kter\u00fd produkuje jak v\u00fdrazn\u00e9 \u00fa\u010dinky na v\u00fddej energie (glukagonov\u00e1 slo\u017eka), tak kanonick\u00e9 \u00fa\u010dinky GLP-1 na sytost\/glyk\u00e9mii, s d\u016frazem zejm\u00e9na na jatern\u00ed v\u00fdsledky:<\/p>\n